Covid update: Pfizer says it will have the ability to supply 1.3bn vaccine doses by the end of next year (if trials and approvals go to plan)
The update was provided in after-hours data reveal by the pharma giant and its partner BioNTech SE
Company
Pfizer Inc
NYSE:PFE
Pfizer Inc is a research-based biopharmaceutical company. The company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1.
293 stories · page 8 of 15
Archive
Wall Street overcomes early deficits to finish the week strong
Wall Street shares closed higher on Friday as Apple shares climbed
Pfizer coronavirus vaccine passes early stage trials
Regulatory review for the candidate is sought as early as October
Archive
FTSE 100 index keeps head above water as traders mull "plethora of risks"
Britain's top share index finished up around four points at 6,211 on the day
Pfizer and BioNTech land US$1.95bn COVID-19 vaccine order from US Government
The deal is for the first 100mln vaccine doses and can be expanded by a further 500mln doses – meanwhile, the clinical trial process continues to advance.
UK government orders 30mln doses of Pfizer and BioNTech COVID-19 vaccine
Pfizer and BioNTech said they expect to start a Phase 2b/3 safety and efficacy trial later this month and seek regulatory review as early as October.
Coronavirus: Pfizer, BioNTech get two vaccine candidates fast-tracked by US authorities
The two formulations showed positive results in early-stage trial data
Pfizer and BioNTech shares jump as early data from coronavirus vaccine trial cheers investors
It was reported that 24 people who received two doses of the vaccine had 'significantly elevated' antibodies within four weeks of the first injection
Pfizer’s coronavirus vaccine candidate enters first phase of US trials
The start of the US trial follows the first jabs administered in Germany last week
How much should a ‘blockbuster’ drug earn now?
While the term for a drug generating US$1bn in turnover has been around since the 1980s, three and a half decades of inflation since then means the sum doesn't go as far as it used to
Pfizer stock climbs as drug giant raises 2019 guidance
The New York drug maker now expects full-year revenue of between $51.2 billion and $52.2 billion
Medexus Pharmaceuticals adds veteran pharma executive to its board
The specialty pharmaceutical company says Adele Gulfo’s addition enhances the board’s commercial and business development expertise
Morgan Stanley doesn’t think there’s much money to be made by investing in GSK
GSK is in the middle of some big changes: it is bedding in a multi-billion-dollar acquisition; rebuilding its drugs pipeline; and merging its consumer healthcare division with one of its rivals
CytoDyn announces two new additions to management team
The company named Brendan Rae as senior vice president of business development and George Bitar as executive director, head of quality
CytoDyn's flagship drug leronlimab to be tested to prevent fatty liver diease in mice
The goal of the exploratory pre-clinical studies are to establish leronlimab’s ability to prevent the progression of Non-Alcoholic Fatty Liver Disease (NAFLD) into NASH
Pharma stocks head south as Trump forces them to display drug prices in TV ads
“Drug companies have to come clean about their prices in TV ads. If drug companies are ashamed of those prices – lower them!”
ChemioCare taps retired Pfizer exec to its board
Roy Waldron joins the biotech company's board after recently retiring from Pfizer, where he spent nearly 20 years
CytoDyn presses forward with HIV treatment after Phase 3
Leronlimab is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Humanigen CEO optimistic on drug candidate after pulling company from the brink
The biotech is in the early stages of work on a drug designed to reduce the sometimes dangerous side effects of a cancer therapy involving altered T cells
Zynerba Pharmaceuticals adds pharma exec to its board
Pamela Stephenson brings expertise in commercial planning to the developer of transdermal cannabinoid therapies